Genmab A/S Reports Capital Increase from Warrant Exercise
Ticker: GNMSF · Form: 6-K · Filed: Aug 12, 2025 · CIK: 1434265
| Field | Detail |
|---|---|
| Company | Genmab A/S (GNMSF) |
| Form Type | 6-K |
| Filed Date | Aug 12, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: capital-increase, employee-warrants, disclosure
TL;DR
Genmab's employees exercised warrants, boosting capital and potentially diluting shares.
AI Summary
Genmab A/S announced on August 12, 2025, a capital increase resulting from the exercise of employee stock warrants. The company filed a Form 6-K to report this event, which is incorporated by reference into several of its S-8 registration statements.
Why It Matters
This filing indicates employee engagement and potential dilution, impacting share structure and ownership.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of a capital increase due to employee stock option exercises, which is a common corporate event.
Key Players & Entities
- Genmab A/S (company) — Filer of the 6-K report
- August 12, 2025 (date) — Date of the company announcement and filing
- 001-38976 (other) — SEC file number for Genmab A/S
- 333-232693, 333-253519, 333-262970, 333-277273 and 333-284876 (other) — File numbers for Genmab A/S's S-8 registration statements
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose is to report a capital increase in Genmab A/S resulting from the exercise of employee warrants, as detailed in a company announcement dated August 12, 2025.
When was this Form 6-K filed?
The Form 6-K was filed on August 12, 2025.
What type of securities were exercised by employees?
Employees exercised warrants.
How does this filing relate to Genmab's registration statements?
This Form 6-K is incorporated by reference into Genmab A/S's registration statements on Form S-8 (File Nos. 333-232693, 333-253519, 333-262970, 333-277273 and 333-284876).
What is the SEC file number for Genmab A/S?
The SEC file number for Genmab A/S is 001-38976.
Filing Stats: 225 words · 1 min read · ~1 pages · Grade level 14.9 · Accepted 2025-08-12 15:11:58
Filing Documents
- gmab_20250812x6k.htm (6-K) — 13KB
- gmab_20250812xx99d1.htm (EX-99.1) — 19KB
- genmab_logoa.jpg (GRAPHIC) — 56KB
- 0001434265-25-000066.txt ( ) — 106KB
From the Filing
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF AUGUST 2025 COMMISSION FILE NUMBER 001-38976 Genmab AS (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F This report on Form 6-K shall be deemed to be incorporated by reference in Genmab AS's registration statements on Form S-8 (File No. 333-232693, 333-253519, 333-262970, 333-277273 and 333-284876 ) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. EXHIBIT INDEX Exhibit Description of Exhibit 99.1 Company Announcement Dated August 12, 2025 Capital Increase in Genmab as a Result of Employee Warrant Exercise SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. GENMAB AS BY s Anthony Pagano Name Anthony Pagano Title Executive Vice President Chief Financial Officer DATE August 12, 2025